홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
NRXS
#4101
Neuraxis, Inc.
7.227
8
USD
+1.66%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+1.66%
월간 변동
-0.24%
6달 변화
+33.11%
년간 변동율
+33.11%
이전 종가
7.110
0
Open
7.240
9
Bid
Ask
Low
7.227
8
High
7.250
0
양
3
마켓
주식
헬스케어
NRXS
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2023
2024
2025
TTM
Key stats
Total common shares outstanding
6.59 M
7.22 M
11.19 M
—
Valuation ratios
Enterprise value
16.75 M
16.74 M
46.25 M
107.35 M
Price to earnings ratio
-0.56
-1.93
-4.78
-11.9
Price to sales ratio
3.36
6.05
11.55
29.82
Price to cash flow ratio
-1.23
-2.67
-6.41
-15.63
Price to book ratio
-5.89
7.88
12.14
16.04
EBITDA 비율에 대한 기업 가치
-1.67
-2.52
-8.24
-15.81
Profitability ratios
Return on assets %
-28.71
-1.73
-1.22
-1.62
Return on equity %
10.42
-3.99
-2.29
-10.64
Return on invested capital %
-7 253.33
-4 413.58
-3 727.78
—
Gross margin %
87.67
86.52
84.23
336.73
Operating margin %
-270.91
-266.46
-219.37
-884.54
EBITDA margin %
-406.85
-247.13
-157.26
-896.28
Net margin %
-594.57
-306.84
-218.55
-881.59
Liquidity ratios
Quick ratio
0.12
1.74
1.96
7.47
Current ratio
0.13
1.75
2.05
7.67
Inventory turnover
14.3
11.05
3.73
7.04
Asset turnover
4.83
1.02
0.64
0.69
Solvency ratios
Debt to assets ratio
0.15
0.73
0.07
0.33
Debt to equity ratio
-0.05
1.68
0.12
1.93
Long term debt to total assets ratio
0
0.66
0.02
0.1
Long term debt to total equity ratio
0
1.53
0.04
0.48
Per share metrics
Operating cash flow per share
-2.06
-0.88
-0.71
-0.74
EBIT per share
-3.09
-0.96
-0.62
-0.96
EBITDA per share
-3.08
-0.96
-0.62
-0.95
Total debt per share
0.02
0.5
0.05
0.19
Cash per share
0.02
0.53
0.55
1.96
Net current asset value per share
0.07
0.62
0.63
2.25
Tangible book value per share
-0.46
0.28
0.34
1.06
Working capital per share
-0.51
0.26
0.32
1.07
Book value per share
-0.43
0.3
0.37
1.14
뉴스
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
The Zacks Analyst Blog Meta, Bank of America, The Procter & Gamble, Espey and NeurAxis
Top Stock Reports for Meta, Bank of America & Procter & Gamble
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
뉴라시스, FDA 승인 후 주가 상승: 복통 치료제
Neuraxis stock rises after FDA clearance for abdominal pain treatment
FDA, 뉴라시스 PENFS 기기 승인 및 시장 확대
뉴라시스, 2025년 3분기 예비 실적 발표...210만 달러 영업 손실
Neuraxis reports preliminary Q3 2025 financial results with $2.1 million operating loss
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis
Top Research Reports for Alphabet, IBM & Merck
Neuraxis enters $3.3 million at-the-market equity offering agreement